Loading
A phase 2 trial of Nirogacestat in desmoid tumour, run by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, active and no longer recruiting.
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) is a phase 2 interventional study registered as NCT07170644 by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, with 20 participants enrolled, started 2025-08-08 and due to reach its primary completion in 2027-05-28. Interventions recorded: Nirogacestat oral tablet. Conditions listed: Desmoid Tumor, Aggressive Fibromatosis. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gamma-secretase inhibitors, Nirogacestat, Desmoid tumour, Small-molecule kinase inhibitors.
Shares Gamma-secretase inhibitors, Nirogacestat, Small-molecule kinase inhibitors.
Shares Nirogacestat, Merck KGaA (EMD Serono), Desmoid tumour.
Shares Gamma-secretase inhibitors, Nirogacestat, Desmoid tumour.
Shares Gamma-secretase inhibitors, Nirogacestat, Small-molecule kinase inhibitors.
Shares Gamma-secretase inhibitors, Nirogacestat, Small-molecule kinase inhibitors.
Shares Nirogacestat, Desmoid tumour.
Shares Merck KGaA (EMD Serono), Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/